<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2113">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05406778</url>
  </required_header>
  <id_info>
    <org_study_id>1001</org_study_id>
    <nct_id>NCT05406778</nct_id>
  </id_info>
  <brief_title>SPARK Neuro REMIND Study</brief_title>
  <official_title>SPARK Neuro Quantitative Resting State EEG Protocol for Assessing Cognitive Impairment and AD Status 'REMIND' Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spark Neuro Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Spark Neuro Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study utilizes investigational software, the SPARK Test, with an FDA-cleared&#xD;
      electroencephalography (EEG) amplifier and EEG cap to collect and then analyze patient EEG&#xD;
      data.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study is to develop an algorithm and then evaluate it to determine whether&#xD;
      applying machine-learning techniques to resting-state electroencephalography (EEG) can&#xD;
      characterize patient's cognitive status and detect the presence or absence of AD on the basis&#xD;
      of the patient's EEG.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 18, 2022</start_date>
  <completion_date type="Anticipated">November 2025</completion_date>
  <primary_completion_date type="Anticipated">May 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Software malfunction occurrences</measure>
    <time_frame>10 weeks</time_frame>
    <description>Report rate of software malfunction occurrences that resulted in a failure to complete a SPARK Test recording.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of patients SPARK Test data</measure>
    <time_frame>10 weeks</time_frame>
    <description>Rate of concordance between SPARK Test score of Alzheimer's Disease (AD) label (positive or negative) with clinical diagnosis&#xD;
Rate of concordance between SPARK Test Cognitive Impairment Index (CII) score predictive of Montreal Cognitive Assessment (MoCA score)&#xD;
Rate of concordance between SPARK Test cognitive status label (unimpaired, Mild Cognitive Impairment (MCI), mild dementia, moderate dementia, severe dementia with unimpaired/MCI/dementia labels operationalized by Clinical Dementia Rating (CDR)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean absolute error for specific cognitive assessment</measure>
    <time_frame>10 weeks</time_frame>
    <description>Mean absolute error for Alzheimer's disease Assessment Scale - 14-item cognitive sbuscale (ADAS-Cog-14), Alzheimer's Disease Cooperative Study Activities of Daily Living (ADCS-ADL), iADRS, CDR and (Mini-Mental State Exam (MMSE)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Alzheimer's Disease positive vs. negative indication for biomarker-confirmed AD</measure>
    <time_frame>10 weeks</time_frame>
    <description>Rate of concordance between SPARK Test predicted Alzheimer's Disease positive/negative for biomarker-confirmed AD as measured by CSF-based markers including amyloid-Beta, Tau, phosphorylated-Tau, proteins related to amyloid processing or PET-based imaging.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">800</enrollment>
  <condition>Alzheimer Disease</condition>
  <condition>Cognitive Impairment</condition>
  <arm_group>
    <arm_group_label>TBD</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SPARK Test</intervention_name>
    <description>Twenty (20) minutes of resting state EEG data collection.</description>
    <arm_group_label>TBD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 55 to 85 at the time of consent&#xD;
&#xD;
          2. Informant available and willing (remotely or in-person) to provide information about&#xD;
             sleep patterns and cognitive functioning who spends &gt;8 hours per week with primary&#xD;
             subject&#xD;
&#xD;
          3. Subject or Legally Authorized Representative (LAR) has the ability to provide informed&#xD;
             consent and comply with the protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Unable to remain still for up to 30 minutes during EEG data recording&#xD;
&#xD;
          2. Subjects currently on and unable to wash out concomitant medications, including: 1)&#xD;
             opiates; 2) benzodiazepines and nonbenzodiazepine hypnotics; 3) sedative&#xD;
             antihistamines; 4) tricyclic anti-depressants; 5) skeletal muscle relaxants; 6)&#xD;
             antiepileptics; 7) antipsychotics; 8) antimanic agents; 9) THC; 10) anticholinergics&#xD;
&#xD;
          3. Previous history of stroke, severe head injury, craniotomy or any other potentially&#xD;
             confounding neurologic illness causing known structural brain damage&#xD;
&#xD;
          4. Medical or psychiatric illness that would interfere with study participation&#xD;
&#xD;
          5. History of epilepsy or chronic seizure disorder&#xD;
&#xD;
          6. Presence of non-dental metal in head&#xD;
&#xD;
          7. Currently experiencing a skin disease on scalp that would affect electrode contacts&#xD;
&#xD;
          8. TICS score indicative of cognitive impairment at screening&#xD;
&#xD;
          9. Substance Use Disorder, including Alcohol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Marinela Gombosev</last_name>
    <phone>929-515-6003</phone>
    <email>study1001@sparkneuro.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Che Lucero</last_name>
    <phone>929-515-6003</phone>
    <email>study1001@sparkneuro.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Voyage Medical</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85282</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Crystal Brown</last_name>
    </contact>
    <investigator>
      <last_name>Ali Imran, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2022</verification_date>
  <study_first_submitted>May 26, 2022</study_first_submitted>
  <study_first_submitted_qc>June 1, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">June 6, 2022</study_first_posted>
  <last_update_submitted>July 6, 2022</last_update_submitted>
  <last_update_submitted_qc>July 6, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>EEG</keyword>
  <keyword>Electroencephalography</keyword>
  <keyword>Machine learning</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

